Jiang Ming-Jie, Lin Chen-Jing, Liu Fu-Rao, Mei Zhu, Gu Dian-Na, Tian Ling
Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Department of Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Heliyon. 2024 May 15;10(10):e31346. doi: 10.1016/j.heliyon.2024.e31346. eCollection 2024 May 30.
Pancreatic cancer is one of the most lethal cancers with significant radioresistance and tumor repopulation after radiotherapy. As a type of short non-coding RNA that regulate various biological and pathological processes, miRNAs might play vital role in radioresistance. We found by miRNA sequencing that microRNA-26a (miR-26a) was upregulated in pancreatic cancer cells after radiation, and returned to normal state after a certain time. miR-26a was defined as a tumor suppressive miRNA by conventional tumor biology experiments. However, transient upregulation of miR-26a after radiation significantly promoted radioresistance, while stable overexpression inhibited radioresistance, highlighting the importance of molecular dynamic changes after treatment. Mechanically, transient upregulation of miR-26a promoted cell cycle arrest and DNA damage repair to promote radioresistance. Further experiments confirmed HMGA2 as the direct functional target, which is an oncogene but enhances radiosensitivity. Moreover, PTGS2 was also the target of miR-26a, which might potentiate tumor repopulation via delaying the synthesis of PGE2. Overall, this study revealed that transient upregulation of miR-26a after radiation promoted radioresistance and potentiated tumor repopulation, highlighting the importance of dynamic changes of molecules upon radiotherapy.
Gastroenterology. 2013-8-2
J Exp Clin Cancer Res. 2018-2-13
Cancer Biol Ther. 2016-5-3
Clin Med Insights Oncol. 2025-8-10
Front Cell Dev Biol. 2025-1-15
ACS Appl Mater Interfaces. 2023-5-17
CA Cancer J Clin. 2023-1
Evid Based Complement Alternat Med. 2022-7-13
Trends Genet. 2021-11
Mol Ther Nucleic Acids. 2021-3-1